Opendata, web and dolomites

PulseHaler

PulseHaler: Improving the Lives of COPD Patients

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 PulseHaler project word cloud

Explore the words cloud of the PulseHaler project. It provides you a very rough idea of what is the project "PulseHaler" about.

first    emphysema    penetration    clinical    safety    countries    reduce    pulmonary    2003    drugs    trade    enhancement    difficulty    goes    core    airflow    collapse    alveolar    et    die    massive    index    zone    minute    people    terminal    treat    efficacy    cigarette    respiratory    device    size    biomass    smoking    air    walk    unprecedented    city    exposure    10    patients    efficiency    venice    drug    capacity    world    kills    270    cough    group    debilitating    pulsehaler    demonstrated    bronchitis    equivalent    invasive       fold    amount    annually    dramatically    stomach    small    ed    functions    improvements    markedly    successfully    named    pollutants    respinova    validated    disease    million    mouth    standard    time    source    cooking    medical    feeling    lung    bronchioles    al    functional    obstructive    progressive    6mw    airways    pharmaceutical    pathophysiology    care    airway    fuels    breathing    adults    approximately    spirometry    entire    limitations    copd    halbert    effect    dyspnoea    history    pollution    inhaled    tests    chronic   

Project "PulseHaler" data sheet

The following table provides information about the project.

Coordinator
RESPINOVA LTD 

Organization address
address: 8 HACHOSHLIM ST.
city: HERZLIYA PITUACH
postcode: 4672408
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Israel [IL]
 Project website http://www.respinova.com
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.1.4. (Active ageing and self-management of health)
2. H2020-EU.2.1.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Information and Communication Technologies (ICT))
3. H2020-EU.2.3.1. (Mainstreaming SME support, especially through a dedicated instrument)
4. H2020-EU.3.1.6. (Health care provision and integrated care)
 Code Call H2020-SMEINST-1-2016-2017
 Funding Scheme SME-1
 Starting year 2017
 Duration (year-month-day) from 2017-12-01   to  2018-04-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    RESPINOVA LTD IL (HERZLIYA PITUACH) coordinator 50˙000.00

Map

 Project objective

Chronic obstructive pulmonary disease (COPD) is a group of progressive, debilitating respiratory conditions, including emphysema and chronic bronchitis, characterized by difficulty breathing, lung airflow limitations, cough, and markedly reduced functional capacity. COPD often is associated with a history of cigarette smoking or exposure to pollutants. It kills approximately 270,000 people in the EU annually, equivalent to the size of the entire city of Venice. It affects 4% and 10% of adults in Europe (Halbert et al., 2003). World-wide 5-10% are affected and 3 million die each year (source: WHO). In the developing countries, COPD has been growing dramatically due to increased air pollution, smoking and massive use of biomass fuels for cooking. Respinova has developed a novel non-invasive technology and medical device named the PulseHaler™, that aims to treat the core of the COPD pathophysiology – small airway collapse. The technology was successfully validated in two clinical studies. In the first study, PulseHaler was evaluated for its ability to open small airways. Clinical results demonstrated unprecedented improvements in the 6 minute walk test (6MW), spirometry lung functions tests and in the feeling of dyspnoea. All of these effects were above and beyond the effect of standard pharmaceutical care. In the second study, PulseHaler™ was successfully used as a new means for improved delivery of inhaled drugs to the terminal bronchioles and the alveolar zone in COPD patients. It resulted in three-fold enhancement of penetration index, a measure of efficiency of drug delivery. By improving the drug delivery, PulseHaler technology can enhance efficacy & safety of drug delivery. It can reduce the amount of drug required, ensure less drug goes to non-lung areas (mouth, stomach etc.), and reduce time required to deliver the drugs.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "PULSEHALER" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "PULSEHALER" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.4.;H2020-EU.2.1.1.;H2020-EU.2.3.1.;H2020-EU.3.1.6.)

CLINICOVERY (2018)

CLINICOVERY, a versatile, high quality, environmental-friendly, easy to use e-Clinical solution for clinical research

Read More  

SensUS (2018)

SensUS: A non-invasive and quantitative ultrasound (QUS) device for an objective monitoring of the childbirth labour process.

Read More  

ImmuneHunter (2017)

Bioinformatics platform for profiling of health: allowing early and accurate detection of multiple diseases simultaneously

Read More